Enfortumab Vedotin
Overview
Enfortumab vedotin is an antibody-drug conjugate designed to target Nectin-4, a cell adhesion molecule highly expressed in urothelial carcinoma and several epithelial malignancies. The molecule consists of a monoclonal antibody linked to monomethyl auristatin E, a microtubule-disrupting cytotoxic agent. After binding to Nectin-4 on tumor cells, the conjugate is internalized and releases the cytotoxic payload intracellularly, leading to cell cycle arrest and apoptosis. Enfortumab vedotin is administered intravenously and is primarily used in advanced or metastatic urothelial carcinoma. The therapy represents a targeted oncology approach that combines selective tumor recognition with delivery of potent chemotherapy directly to cancer cells. Its clinical role has expanded significantly in patients who have progressed after platinum-based chemotherapy or immune checkpoint inhibitors and in combination treatment strategies for previously untreated advanced disease.
Background and Date of Approval
Enfortumab vedotin was developed as a targeted antibody-drug conjugate for urothelial carcinoma with high Nectin-4 expression. The United States Food and Drug Administration granted accelerated approval on December 18, 2019 for adult patients with locally advanced or metastatic urothelial carcinoma who had previously received a programmed death receptor-1 or programmed death-ligand 1 inhibitor and platinum-containing chemotherapy. On July 9, 2021, regular approval was granted following confirmatory clinical trial data demonstrating improvement in overall survival and response rates. Subsequently, on April 3, 2023, the United States Food and Drug Administration approved enfortumab vedotin in combination with pembrolizumab for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma. Additional expanded approval for broader first-line use in combination with pembrolizumab was granted on December 15, 2023 based on Phase III EV-302 clinical trial results demonstrating significant survival benefit. Regulatory approvals have also been granted in multiple international regions including the European Union and Japan.
Uses
Enfortumab vedotin is indicated for the treatment of adults with locally advanced or metastatic urothelial carcinoma. It may be used as monotherapy in previously treated patients or in combination with pembrolizumab in selected first-line settings. The therapy is particularly relevant in patients who are not eligible for cisplatin-containing chemotherapy or who have progressed following prior systemic treatment. Research is also ongoing in additional Nectin-4 expressing malignancies.
Administration
Enfortumab vedotin is administered as an intravenous infusion on specified days of a 28-day treatment cycle. Dosing is based on body weight and may require modification depending on toxicity and tolerability. Treatment is continued until disease progression or unacceptable adverse effects occur. Patients require routine clinical and laboratory monitoring throughout therapy.
Side Effects
Common side effects include fatigue, peripheral neuropathy, rash, decreased appetite, nausea, diarrhea, altered taste sensation, dry skin, and hair loss. Hyperglycemia and infusion-related reactions may also occur. These adverse effects are often manageable with supportive care and dose modifications when necessary.
Warnings
Serious risks include severe skin reactions such as Stevens-Johnson syndrome and toxic epidermal necrolysis, severe hyperglycemia, peripheral neuropathy, pneumonitis, and ocular disorders. Infusion-related reactions and severe infections may also occur. Fetal harm can occur during pregnancy due to the cytotoxic mechanism of action. Prompt interruption or discontinuation may be required in cases of severe toxicity.
Precautions
Patients should undergo baseline assessment including blood glucose monitoring, liver function evaluation, and neurological assessment. Caution is required in patients with pre-existing neuropathy or poorly controlled diabetes mellitus. Enfortumab vedotin may interact with strong CYP3A4 inhibitors or inducers affecting metabolism of the cytotoxic payload. Monitoring for dermatologic toxicity and pulmonary symptoms is essential during treatment.
Expert Tips
Enfortumab vedotin should be considered in patients with advanced urothelial carcinoma who are unsuitable for or have progressed after conventional therapies. Early recognition of skin toxicity and neuropathy is important to prevent severe complications. Blood glucose levels should be monitored carefully even in patients without known diabetes. Coordination between oncology, dermatology, and supportive care teams may improve management of adverse events. Patient counselling should emphasize prompt reporting of rash, breathing difficulties, neurological symptoms, or vision changes.